Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT

F. Scalorbi1,2*, G. Argiroffi3, M. Baccini2, L. Gherardini2, V. Fuoco1, N. Prinzi3, S. Pusceddu3, E. M. Garanzini4, G. Centonze5, M. Kirienko1, E. Seregni1, M. Milione5 & M. Maccauro1

To develop predictive models of side effect occurrence in GEPNET treated with PRRT. Metastatic GEPNET patients treated in our centre with PRRT (177Lu-Oxodotreotide) from 2019 to 2020 were considered. Haematological, liver and renal toxicities were collected and graded according to CTCAE v5. Patients were grouped according with ECOG-PS, number of metastatic sites, previous treatment lines and therapies received before PRRT. A FLIC model with backward selection was used to detect the most relevant predictors. A subsampling approach was implemented to assess variable selection stability and model performance. Sixty-seven patients (31 males, 36 females, mean age 63) treated with PRRT were considered and followed up for 30 weeks from the beginning of the therapy. They were treated with PRRT as third or further lines in 34.3% of cases. All the patients showed at least one G1–G2, meanwhile G3–G5 were rare events. No renal G3–G4 were reported. Line of PRRT administration, age, gender and ECOG-PS were the main predictors of haematological, liver and renal CTCAE. The model performance, expressed by AUC, was > 65% for anaemia, creatinine and eGFR. The application of FLIC model can be useful to improve GEPNET decision-making, allowing clinicians to identify the better therapeutic sequence to avoid PRRT-related adverse events, on the basis of patient characteristics and previous treatment lines.

Neuroendocrine tumors (NETs) are a heterogeneous group of well differentiated neoplasms, considered rare malignancies, even if the incidence has increased more than 6 times in the last decades1. Gastroenteropancreatic Neuroendocrine Tumors (GEPNET) constitutes a subgroup of NETs which are diagnosed as low-grade lesions in the majority of cases. The Surveillance, Epidemiology End Results (SEER) database has estimated an incidence of 3.56/100,000 per year in the USA. The incidence in Europe appears to be lower and ranges between 1.33 and 2.33/100,000 per year, although the data are retrospective and heterogeneous2–4. According to WHO 2019 classification5, the GEPNETs are classified into three groups, on the basis of the proliferation index (Ki-67) and the number of mitotic figures per 2 mm2. Ki-67 < 3% and/or mitotic index < 2 HPF (high power fields) are classified as G1, Ki-67 3–20% and/or mitotic index 2–20 HPF (high power fields) are classified as G1, Ki-67 3–20% and/or mitotic index 2–20 HPF as G2 and Ki-67 > 20% and/or mitotic index > 20 HPF as G3.

Although GEPNET are considered low-growing tumors, up to 90% of patients have lymph node metastasis and in 45–70% of cases liver metastasis are present at the time of diagnosis6,7. Surgery of primary tumor represents the only curative treatment, with a 5-year survival rate between 60–80%. In case of liver metastasis, only 5–15% of patients are eligible for liver metastasIs resection7,8. At the present, Somatostatin Analogues (SSA) represents the first treatment in the management of unresectable disease, reducing both hormone production and tumor growth. In case of progression, even after SSA dosage increase, local or systemic approaches have to be considered. The burden of disease, the location of primary tumor and metastasis as well as the tumor biology are the main aspects to consider in the treatment choice. For oligometastatic liver disease, a loco-regional approach can be applied as ablation or trans-arterial chemoembolisation (TACE) or radioembolisation (TARE). In case of progressive metastatic spread, a systemic approach is required and must be selected in accordance with the...
primary tumor localisation. For midgut patients, PRRT and everolimus (an mTOR inhibitor) are the two main choices. For foregut patients the choices are multiple, starting from molecular targeting therapies (everolimus and Sunitinib (a tyrosine kinase inhibitor)), following with alkylating chemotherapies as Capecitabine and Temozolomide combination to end with PRRT.

Since metastatic GEPNET are low-growing neoplasms, characterised by stability followed by progression, multiple lines of treatment have to be adopted to control distant localisations and symptoms. Hence, therapy-related adverse events can occur during the course of the disease and can forbid further therapeutic lines. Currently, there are some guidelines and flow chart to support decision making in order to assess the best treatment choice according to disease burden, somastostatin receptor expression and previous treatment protocols. Nevertheless, each case features specific conditions and frequently requires a custom evaluation. In this scenario, there are no precise models to assess the occurrence of adverse events during PRRT protocol in GEPNET patients treated with previous lines of systemic therapies. The Lu-DOTATATE PRRT, a recently approved target therapy (EMA, AIFA), can be applied in second or further line in well differentiated disease, after SSA failure. Actually, the sequence and timing of treatments are frequently related to single-centre experience, in particular in case of foregut NET for which no specific guidelines are available. For midgut patients in the majority of cases PRRT is administered as second line, after SSA failure. The variability in PRRT treatment line can deeply impact on therapy effectiveness, being a real cause of PRRT discontinuation related to haematological, hepatic or renal toxicities. To nowadays, there are only some retrospective publications regarding the evaluation of PRRT adverse events in correlation with previous line of treatments, showing associations between treatment choice and toxicities development.

The aim of this study is to investigate the occurrence of adverse events in GEPNET patients during radio-metabolic treatment and to evaluate the role of previous therapies and individual characteristics in predicting treatment-related toxicities. Considering that G3-G4 toxicities are rare events during PRRT treatment, issues related to perfect prediction occurred in the analysis of our dataset (data separation). Therefore, we adopted a penalised regression approach based on the Firth’s logistic regression with intercept correction (FLIC model) to solve this problem. A backward selection procedure was implemented to detect the most relevant predictors.

Patients and methods

Data collection. We collected data from a cohort of 87 consecutive patients with G1-G2 GEPNETs, scheduled to receive PRRT through the Foundation IRCCS, Istituto Nazionale Tumori, Milan, from April 2019 to December 2020. All the patients were treated with 177Lu-Oxodotretide (Lutathera®), 7.4 GBq iv per administration, interval 8 weeks (+/- 2 weeks), following EMA and AIFA indications. Patients were treated with 1 to 4 PRRT administrations and were all previously treated with SSA, followed by disease progression confirmed by CT or MRI scan. The analysis was performed on the subset of patients enrolled from April 2019 to June 2020 (n = 67), following up them for 30 weeks from the first PRRT administration. Before PRRT, tumor burden and somastostatin receptor expression were evaluated by CT/MRI scan and 68 Ga-DOTA-SSA PET/Octreoscan, respectively. Inclusion criteria were: age ≥ 18 years, histopathological diagnosis of well differentiated G1 or G2 (WHO 2019) GEPNET, at least one previous line of treatments with SSA and a CT/MRI scan performed before PRRT, repeated after 2 administrations. Haematopoietic, liver and renal functions before the first PRRT administration were considered as reference baseline. Hematochemical tests were re-evaluated every 14 days during the whole treatment; haematological, renal and liver toxicities were graded applying Common Terminology Criteria for Adverse Events version 5.0 (CTCAE) and the nadir values were reported per patient. Haematopoietic toxicities were evaluated considering anaemia, white blood cells (WBC), neutrophils and platelets counts, ALT/GPT (alanine aminotransferase), AST/GOT (aspartate aminotransferase), GGT (gamma glutamyl transpeptidase), total bilirubin, albuminaemia and INR values were considered to evaluate liver function alteration. To assess renal function, creatinine clearance and eGFR values were considered. Since eGFR can be correctly assessed only in patients younger than 75 years, older patients have been excluded from the statistical analysis of this outcome. Exclusion criteria were: age < 18 years, absence of primary tumors diagnosis, absence of radiological and nuclear medicine imaging evaluation (baseline and interim), absence of signed informed consent.

The Performance Status was assessed by ECOG score, before PRRT treatment. The study population was subdivided as midgut/foregut in relation to primary tumor localisation and as G1 or G2 in accordance with WHO 2019 classification (data were extracted from pathological reports). In doubtful cases, a pathological evaluation of paraffin samples was required. The site of secondary localisations as well as the number of metastatic organs involved were evaluated per patient. Furthermore, previous lines of treatment were evaluated and patients were grouped as follows: PRRT as second or as third/further line of treatment. The following previous therapies were also considered as possible predictive factors of CTCAE onset: splenectomy, everolimus, alkylating chemotherapy and MetNET protocol (Lanreotide and Metformin). Surgical resection of primary tumor, loco-regional therapies and liver transplantation were not included in the lines of treatment, nor SSA shift or SSA increase dosage.

Ethical approval. This observational study was approved by the Ethical Committee of National Institute for Tumor of Milan (Study number: INT 6/20) and was conducted in accordance with the Principles of Declaration of Helsinki (1964). All the patients have given written informed consent for the participation in the study.

Statistical analysis. The collected variables were summarized as mean (± standard deviation) when continuous and as frequency and percentage (%) when categorical. The crude associations between occurrence of adverse events and patient characteristics, including previous treatments, were evaluated by Fisher's test and Chi square test. Age differences between groups were evaluated by Wilcoxon's test.
With the aim of investigating the association between the occurrence of each specific adverse event and the covariates (primary localisation, WHO grading, patient characteristics, treatment lines, number of previous therapies, number of secondary localisations), a FLIC model was specified. The FLIC model modifies the more known Firth's logistic regression, which is widely used to overcome separation problem frequently arising when, as in our application, the logistic regression is applied to relatively small datasets, with rare events, characterized by unbalanced distribution of the risk factors between outcome categories and high correlation between explanatory variables. The FLIC model introduces a post-hoc adjustment of the intercept of the Firth's logistic regression providing unbiased predictive probabilities. A backward procedure for variable selection was used to detect the patient's characteristics that were more predictive of the outcomes.

The predictive performances of the procedure and the stability of the variable selection were assessed by using a subsampling approach. In particular, we generated 100 subsamples from the original dataset by repeatedly sampling 63.2% of the subjects, with no repetitions. Then we performed on each subsample the previously described analysis, obtaining 100 different backward selection results. We calculated for each covariate the frequency of selection and the mean absolute effect over the 100 repetitions. Finally, the Area Under the ROC Curve (AUC) was calculated for each selected model on 36.8% of patients not included in the subsample. The overall predictive performance was calculated as average AUC over the 100 repetitions.

STATA v16.0 was used for data management and descriptive analyses. The analysis based on FLIC logistic regression has been performed by using the package logistF of R software.

**Results**

In Table 1 we described the cohort of 67 patients (31 (46.3%) males, 36 (53.7%) females, mean age 63 years, SD ± 11, 95% CI 60.4–65.6) included in the analysis. According to the primary localisation and WHO 2019 classification, 38 (56.7%) patients were classified as midgut, 29 (43.3%) as foregut meanwhile 24 (35.8%) as G1 and 43 (64.2) as G2. Evaluating ECOG performance status before PRRT, 55 (82.1%) patients were classified as ECOG 0 and 12 (17.9%) as ECOG 1 or 2. Metastasis were diagnosed in all the patients and, in the majority of cases, were located in the liver (66, 98.5%), followed by lymph nodes (37, 56.1%) and bone (23, 34.8%) (Table 1). Sixty-one (91%) patients performed all the 4 PRRT administrations, 64 (95.5%) at least three and 66 (98.5%) at least two. Of the six patients who did not complete the entire cycle of radiometabolic treatment, two interrupted it due to toxicity occurrence, the remaining four due to clinical/radiological progression. One of these four patients died therefore, PRRT protocol was completed. No G3–G4 renal toxicities were reported. All the patients showed at procedures to restore normal values. In all the other cases the G3–G4 alterations were transitional events and, the same patient were the cause of PRRT discontinuation, after the third administrations, and required medical procedures to restore normal values. In all the other cases the G3–G4 alterations were transitional events and, therefore, PRRT protocol was completed. No G3–G4 renal toxicities were reported. All the patients showed at least one G1–G2 CTCAE during PRRT protocol, in particular eGFR alteration (44, 75.9%), followed by anaemia (46, 68.6%), thrombocytopenia (32, 47.8%) and leukopenia (30, 44.8%). Since eGFR was assessed in 58 patients only, in accordance with age cut-off, the percentage of G1–G2 resulted particularly high although the absolute number of cases was comparable with anaemia occurrence (44 versus 46, see also Table 2).

Table 2 illustrates the occurred toxicities and highlights that G3–G4 CTCAE were extremely rare events, reported in 5 (7.5%) cases considering haematological alterations (2 neutropenia, 1 anaemia, 2 thrombocytopenia) and 2 (3%) cases for liver alteration (1 ALT and 1 INR). Anaemia and thrombocytopenia occurred in the same patient were the cause of PRRT discontinuation, after the third administrations, and required medical procedures to restore normal values. In all the other cases the G3–G4 alterations were transitional events and, therefore, PRRT protocol was completed. No G3–G4 renal toxicities were reported. All the patients showed at least one G1–G2 CTCAE during PRRT protocol, in particular eGFR alteration (44, 75.9%), followed by anaemia (46, 68.6%), thrombocytopenia (32, 47.8%) and leukopenia (30, 44.8%). Since eGFR was assessed in 58 patients only, in accordance with age cut-off, the percentage of G1–G2 resulted particularly high although the absolute number of cases was comparable with anaemia occurrence (44 versus 46, see also Table 2).

The marginal association between the reported CTCAE, patient's characteristics, the number of previous treatment lines, the previous alkylating chemotherapy, everolimus, MetNET and splenectomy was assessed. Pearson's chi square, Fisher's and Wilcoxon's test were applied to the frequencies of events. Relevant associations were observed for: aging and eGFR increase, female gender and anaemia, ECOG-PS 1–2 and increase of creatinine level, line of PRRT administration and increased GGT level. Splenectomy was inversely associated with thrombocytopenia and ALT/GPT increase. Table 3 shows in detail the results and the correspondent p values. No crude associations were reported between previous treatment with everolimus or chemotherapy and CTCAE occurrence.

Performing standard logistic regression analysis on the adverse event outcomes of interest, we obtained extremely high OR estimates for many covariates, with huge standard errors and wide confidence intervals, for the effect of data separation (data not reported). As shown in Table 4, under FLIC model these phenomena are partly, even if not completely, reduced. Line of PRRT administration is selected as predictor of anaemia (logOR 5.63, PRRT in second line as reference category), thrombocytopenia (logOR 1.54), neutropenia (logOR 0.99), GGT increase (logOR 1.88) and albuminaemia decrease (logOR < 0.01). However, the inclusion frequency (obtained from subsampling procedure) are quite low (see Fig. 1). Gender is a predictor of anaemia (logOR 1.98, male as reference category), leukopenia (logOR 1.02), thrombocytopenia (logOR -1.08) and creatinine increase (logOR – 1.84), with frequency of inclusion larger than 60% for anaemia and creatinine. Age, modelled as continuous variable, is selected as predictor of thrombocytopenia (logOR 0.05), creatinine (logOR,0.08), eGFR (logOR 0.14), bilirubin (logOR 0.05) and albumine (logOR -0.61) with frequencies of inclusion > 50% only for creatinine and eGFR. Splenectomy is a protective factor of thrombocytopenia (logOR -2.9) and leukopenia (logOR -2.32), with high inclusion frequencies, and of ALT increase (logOR -2.25) with an inclusion frequency < 30% (Fig. 1).
Unexpectedly, chemotherapy was not a predictive factor of CTCAE onset. Everolimus was found to be a strong predictor (logOR 2.98) of creatinine increase but the inclusion frequency resulted low (Table 4 and Fig. 1). Renal toxicity was also evaluated by eGFR decrease, the predictor of which was WHO grading (logOR 1.42) but the inclusion frequency resulted low. The FLIC penalisation appears to have a poor effect in reducing separation on the albumin model, with huge coefficients for everolimus and ECOG performance status (Table 4).

Table 5 reports the average AUC, calculated for each outcome. The predictive performance of the model is above 65% for the following outcomes: anaemia, creatinine and eGFR. The mean absolute effects of the covariates arisen from subsampling are reported in the Tab S1.

| Age | n = 67 |
|-----|--------|
| Mean (± SD) | 63 (± 11) |
| > 60 ys | 38 (56.7) |

| Gender | n (%) |
|--------|-------|
| Male   | 31 (46.3) |
| Female | 36 (53.7) |

| ECOG PS |  |
|---------|--------|
| 0       | 55 (82.1) |
| 1_2     | 12 (17.9) |

| Grading (WHO 2017) |  |
|---------------------|--------|
| G1                  | 24 (35.8) |
| G2                  | 43 (64.2) |

| Primary tumor |  |
|---------------|--------|
| Midgut        | 38 (56.7) |
| Foregut       | 29 (43.3) |

| Distant metastasis localisation |  |
|--------------------------------|--------|
| Liver                          | 66 (98.5%) |
| Nodes                          | 37 (56.1) |
| Bone                           | 23 (34.8) |
| Mesentery                      | 11 (16.7) |
| Peritoneum                     | 7 (10.6) |
| Lung                           | 1 (1.5) |
| Other localisations            | 7 (10.6) |

| PRRT administrations |  |
|----------------------|--------|
| I                    | 67 (100) |
| II                   | 66 (98.5) |
| III                  | 64 (95.5) |
| IV                   | 61 (91) |

| PRRT line of treatment |  |
|------------------------|--------|
| 2nd                    | 45 (67.2) |
| Midgut                 | 30 (78.9)* |
| Foregut                | 15 (51.8)* |
| 3rd                    | 13 (19.4) |
| Midgut                 | 6 (15.8)* |
| Foregut                | 7 (24.1)* |
| 4th or further         | 9 (13.4) |
| Midgut                 | 2 (5.3)* |
| Foregut                | 7 (24.1)* |

| Previous therapies |  |
|--------------------|--------|
| Surgery            | 49 (73.1) |
| Loco-regional (TACE, TARE, RT) | 12 (17.9) |
| Splenectomy        | 11 (16.4) |
| Alkylating chemotherapy | 13 (19.4) |
| mTOR inhibitor (Everolimus) | 13 (19.4) |
| MetNET protocol    | 5 (7.5) |

Table 1. Selected study population. TACE, transarterial chemoembolisation; TARE, transarterial radioembolisation. *percentage calculated considering midgut and foregut separately.
Discussion

The safety of PRRT treatment has been confirmed by many studies, starting with the Rotterdam experience of Kwekkeboom, moving to the NETTER-1 published by Strosberg, ending with the recent paper of Chen regarding an elderly cohort. In comparison with these studies, we have reported a similar proportion of G3-G4 CTCAE (8.96%, only 6 patients on 67 showed severe adverse events). As expected, bone marrow toxicities were the most common G3-G4 events (5 cases on 7, 71.4%), if compared to renal and liver ones. In our study we have reported no G3-G4 renal toxicities, in accordance with NETTER-1, Chen and Fross-Baron studies. We found that there is a marginal association between splenectomy and the risk of leukopenia and thrombocytopenia (Table 3); this highlights how surgical spleen removal is a protective factor of the reported haematological toxicity. In a recent study Medaer et al. observed significantly lower level of leukopenia, lymphopenia and thrombocytopenia in the cohort pre-treated with splenectomy.

Line of PRRT administration resulted to be frequently selected as a predictor of CTCAE. In particular, patients treated with PRRT as third or further line have a higher probability to develop, during radio-metabolic treatment, anaemia, thrombocytopenia, neutropenia, GGT increase and albuminaemia decrease. However, on the basis of the subsampling procedure, the frequencies of inclusion of PRRT line in the models were quite low, with the exception of the one calculated for the GGT increase model. Therefore, if our results are suggestive of a possible role of line of PRRT in the occurrence of CTCAE, on the other hand our conclusions regarding this predictor

| Adverse events          | G1-G2, n(%) | G3-G4, n(%) | Total CTCAE, n(%) |
|-------------------------|------------|------------|------------------|
| Leukopenia              |            |            |                  |
| midgut                  | 30 (44.8)  |            | 30 (44.8)        |
| foregut                 | 19 (63.3)  |            | 19 (63.3)        |
| Neutropenia             | 16 (23.9)  | 2 (3)      | 18 (26.9)        |
| midgut                  | 9 (56.3)   | 1 (50)     | 10 (55.6)        |
| foregut                 | 7 (43.7)   | 1 (50)     | 8 (44.4)         |
| Anaemia                 | 46 (66.6)  | 1 (1.5)    | 47 (70.1)        |
| midgut                  | 28 (56.5)  | 1 (100)    | 29 (57.5)        |
| foregut                 | 20 (43.5)  |            | 20 (42.5)        |
| Thrombocytopenia        | 32 (47.8)  | 2 (3)      | 34 (50.7)        |
| midgut                  | 21 (65.6)  | 1 (2.6)    | 22 (64.7)        |
| foregut                 | 10 (31.3)  | 1 (3.5)    | 11 (32.4)        |
| ALT/GPT increase        | 21 (31.3)  | 1 (1.5)    | 22 (32.8)        |
| midgut                  | 10 (47.6)  |            | 10 (45.4)        |
| foregut                 | 11 (52.4)  | 1 (100)    | 12 (54.5)        |
| AST/GOT increase        | 17 (25.4)  |            | 17 (25.4)        |
| midgut                  | 8 (47.1)   |            | 8 (47.1)         |
| foregut                 | 9 (52.9)   |            | 9 (52.9)         |
| GG T increase           | 12 (17.9)  |            | 12 (17.9)        |
| midgut                  | 3 (25)     |            | 3 (25)           |
| foregut                 | 9 (75)     |            | 9 (75)           |
| Total bilirubin increase| 17 (25.4)  |            | 17 (25.4)        |
| midgut                  | 8 (47.1)   |            | 8 (47.1)         |
| foregut                 | 9 (52.9)   |            | 9 (52.9)         |
| Albumin decrease        | 4 (6)      |            | 4 (6)            |
| midgut                  | 2 (50)     |            | 2 (50)           |
| foregut                 | 2 (50)     |            | 2 (50)           |
| INR increase            | 6 (9)      | 1 (1.5)    | 7 (10.5)         |
| midgut                  | 2 (33.3)   | 1 (2.6)    | 3 (42.9)         |
| foregut                 | 4 (66.6)   |            | 4 (57.1)         |
| Creatinine clearance    | 16 (23.9)  |            | 16 (23.9)        |
| midgut                  | 10 (62.5)  |            | 10 (62.5)        |
| foregut                 | 6 (37.5)   |            | 6 (37.5)         |
| eGFR decrease (n:58)**  | 44 (75.9)  |            | 44 (75.9)        |
| midgut (n: 31)          | 23 (47.7)  |            | 23 (47.7)        |
| foregut (n: 27)         | 23 (52.3)  |            | 23 (52.3)        |

Table 2. Occurred CTCAE. *Percentages calculated in accordance with the number of patients (n = 67). The numbers that are highlighted in bold are referred to the most frequent reported adverse events. **eGFR alteration was assessed in 58 patients, in accordance with age cut-off.
Table 3. P-values of Chi square/Fisher tests to evaluate the association between CTCAE and the independent variables; p-value of Wilcoxon's test for variable Age. Bold values indicate statistical significance, in accordance with the conventionally accepted threshold (< 0.05). Thr-paenia: thrombocytopaenia.

| Explanatory variables | Leukopaenia | Neutropaenia | Anaemia | Thir-paenia | ALT increase | AST increase | GGT increase | Bil increase | Alb decrease | INR increase | Creatinine increase | eGFR decrease |
|-----------------------|-------------|--------------|---------|-------------|--------------|--------------|-------------|-------------|-------------|-------------|-----------------|---------------|
| Age                   | 0.589       | 0.547        | 0.255   | 0.757       | 0.483        | 0.775        | 0.315       | 0.758       | 0.278       | 0.436       | 0.032           |
| Gender                | 0.219       | 0.583        | *0.003* | 0.028       | 0.298        | 1            | 0.524       | 0.269       | 0.329       | 0.696       | 0.011           | 0.378         |
| ECOG-PS               | 1           | 0.720        | 0.091   | 0.539       | 1            | 0.715        | 1           | 0.678       | 1           | 0.144       | 0.6             | *0.029*       | 0.322         |
| Grading               | 1           | 0.567        | 0.405   | 0.131       | 1            | 1            | 1           | 0.574       | 1           | 0.407       | 1               | 0.118         |
| Liver                 | 1           | 0.069        | 0.511   | 1           | 0.538       | 1            | 0.328       | 1           | 1           | 0.423       | 0.428           |
| Nodal                 | 1           | 0.592        | 1       | 0.627       | 0.792       | 0.386        | 0.755       | 0.168       | 1           | 0.036       | 1               | 0.574         |
| Mesenteric            | 0.199       | 0.282        | 0.034   | 0.48        | 0.053        | 1            | 1           | 1           | 0.323       | 0.438       | 0.673           |
| Peritoneal            | 0.692       | 0.375        | 0.094   | 0.259       | 0.416        | 1            | 1           | 1           | 0.669       | 1           | 1               |
| Bone                  | 0.608       | 0.773        | 0.402   | 0.102       | 0.504       | 0.718        | 0.116       | 1           | 0.56        | 0.113       | 0.221           | 0.77          | 0.338         |
| Lung                  | 0.448       | 1            | 0.493   | 1           | 0.005       | 0.547        | 1           | 0.56        | 0.113       | 0.221       | 0.77            | 0.338         |
| PRRT line             | 0.082       | 0.166        | 0.102   | 0.504       | 0.718       | 0.116        | 1           | 0.56        | 0.113       | 0.221       | 0.77            | 0.338         |
| Chemo-therapy         | 0.759       | 0.312        | 0.315   | 0.765       | 0.499        | 0.715        | 0.228       | 0.725       | 1           | 0.127       | 1               | 0.424         |
| Everolimus            | 0.759       | 0.736        | 0.74    | 0.369       | 0.465        | 1           | 0.158       | 0.167       | 0.614       | 0.274       | 0.691           |
| MetNET                | 0.650       | 0.116        | 1       | 0.197       | 0.316       | 0.588        | 0.216       | 0.099       | 1           | 0.081       | 1               | 0.563         |
| Splenectomy           | 0.017       | 0.714        | 1       | 0.006       | 0.024        | 1           | 0.099       | 1           | 1           | 0.274       | 0.424           |

are not particularly strong. We would like to point out that, to nowadays, there are no studies that have correctly assessed line of PRRT as a predictive factor of CTCAE onset.

In our analysis no increased risks of CTCAE have been found in patients pre-treated with alkylating chemotherapy (Tables 3, 4). Similar results have been reported by Bergsma et al. in 2015 and Rudisile in 2019. To note, in our study, alkylating chemotherapy was the previous treatment in 19.4% of patients (Table 1b), a percentage that is comparable to the one reported by Rudisile (20%) but not to Bergsile (12%). Fross-Baron evaluated PRRT safety in pancreatic NET heavily pre-treated with chemotherapy, showing that bone marrow toxicity was unrelated to type and length of chemotherapy. Conversely, Chen et al. reported an increased trend of G3-G4 CTCAE onset in patients who received chemotherapy before PRRT, without reaching statistical significance.

In line with the literature, our results showed that previous treatment with everolimus is not a strong predictor of adverse events occurrence during PRRT (Table 4). Indeed, even if everolimus has been selected in some models as predictor, its frequencies of inclusion were always low (Fig. 1). Medaer et al. have shown no significant differences in the number of haematological CTCAE reported during PRRT between patients pre-treated with everolimus and/or Sunitinib and patients not pre-treated with target therapies. To note, neither renal nor liver toxicity was assessed in the study. Panzuto et al. have highlighted how patients previously treated with PRRT and chemotherapy have a 12-fold increased risk of severe toxicity (G3–G4) when treated with everolimus, compared to 3.68-fold for chemotherapy only and 2.58 for PRRT only.

In our study, the major predictor of liver function alteration, expressed as GGT increase, is the line of PRRT administration. The frequency of inclusion of this covariate in the GGT predictive model is quite high, indicating good reproducibility of this result. Fatal liver toxicity was reported in a single case by Fross-Baron meanwhile Chen et al. reported a G3/G4 case of ALP/GGT increase, correspondent to 1.4% of all the G3/G4 reported events. Furthermore, in our study, the localisation of primary tumor (midgut versus foregut) resulted a predictor of INR increase and albumine decrease but with quite low frequencies of inclusions. The strongest predictors of renal toxicity were gender (with higher risk for males) and age (increasing risk with age), with good frequency of inclusion in the model.

Since G3-G4 are rare occurrence, classical logistic regression is not the most effective approach to be used in particular in small datasets. Indeed, in these settings, extreme regression coefficient estimates and very wide confidence intervals can be obtained. The Firth’s model has been successfully applied in different clinical fields, for example to predict major bleeding among patients using anticoagulants, to identify rare anaesthesia-related risk factors in children and to predict rare adverse events occurrence after vaccination. At the best of our knowledge there are no applications of this model to predict CTCAE in GEPTNET patients.

Our analysis suggests that line of PRRT administration, age, gender and ECOG performance status are possible predictors of CTCAE. For several outcomes, these results are confirmed by the internal validation based on subsampling procedure. The predictive performance of our models, assessed by AUC, was quite poor for several outcomes, due to the small sample size and the low number of events observed in our dataset. However, the performance of anaemia, creatinine and eGFR predictive models was good, suggesting the reproducibility of the results for these outcomes.
The FLIC model appears to be a promising method for prediction of CTCAE in the GEPNET management. Approaches similar to the one used in this paper can address clinician decision making, modifying treatment sequencing or suggesting radiodrug reduction activity. However, this study has some major limitations related to the small sample size, the low number of G3-G4 adverse events and the absence of an external validation. Further investigations, including multicentre studies, will be planned to improve the knowledge regarding the predictive factors of CTCAE in GEPNET patients.

**Conclusion**

The development of predictive models would be extremely useful to improve GEPNET patient decision making and to avoid PRRT-related adverse events onset. CTCAE occurrence during PRRT treatment can be assessed applying penalised approaches like FLIC model. Subsampling procedure is a useful tool to perform internal validation of the model. External validation is needed before clinical implementation.

**Table 4.** FLIC logistic regression. Estimated associations are expressed as OR and logOR. #: hyper-inflated estimates, not reported.

| Outcome         | Covariates                  | Comparison          | OR  | Log OR | Lower CI | Upper CI |
|-----------------|-----------------------------|---------------------|-----|--------|----------|----------|
| Anaemia         | PRRT Line                   | > 2 vs 2 (ref)      | 279.82 | 5.63   | 0.39     | 11.66    |
|                 | ECOG-PS                     | 1–2 vs 0 (ref)      | 17.13 | 2.84   | 0.12     | 5.80     |
|                 | Gender                      | female vs male (ref)| 7.26 | 1.98   | 0.71     | 3.25     |
|                 | MetNET                      | yes vs no (ref)     | 0.02 | 3.80   | 8.93     | 1.32     |
|                 | Everolimus                  | yes vs no (ref)     | 0.01 | 4.90   | 10.78    | 0.97     |
| Thrombocyto-paenia | PRRT Line                   | > 2 vs 2 (ref)      | 4.66 | 1.54   | 0.14     | 2.94     |
|                 | Age                         | (continuous)        | 1.05 | 0.05   | -0.01    | 0.11     |
|                 | Gender                      | female vs male (ref)| 0.34 | 1.08   | 2.25     | 0.08     |
|                 | Grading WHO2019             | G2 vs G1 (ref)      | 0.29 | 1.24   | 2.49     | 0.01     |
|                 | Splenectomy                 | yes vs no (ref)     | 0.06 | 2.90   | 5.29     | -0.51    |
| Leukopaenia     | Gender                      | female vs male (ref)| 2.76 | 1.02   | 0.04     | 2.08     |
|                 | Splenectomy                 | yes vs no (ref)     | 0.10 | 2.32   | 4.23     | -0.40    |
| Neutropaenia    | PRRT Line                   | > 2 vs 2 (ref)      | 2.70 | 0.99   | -0.12    | 2.11     |
| INR increase    | MetNET                      | yes vs no (ref)     | 7.47 | 2.01   | 0.03     | 4.00     |
| AST increase    | (null model)                |                     |     |        |          |          |
| ALT increase    | Middgut-Foregut             | foregut vs middgut (ref) | 3.44 | 1.24   | 0.00     | 2.47     |
|                 | N° of metastasis            | (continuous)        | 0.51 | 0.68   | -1.35    | -0.01    |
|                 | Splenectomy                 | yes vs no (ref)     | 0.11 | 2.25   | -4.32    | -0.18    |
| GGT increase    | PRRT Line                   | > 2 vs 2 (ref)      | 6.56 | 1.88   | 0.22     | 3.54     |
|                 | Middgut-Foregut             | foregut vs middgut (ref) | 3.81 | 1.34   | 0.09     | 2.77     |
|                 | Everolimus                  | yes vs no (ref)     | 0.17 | 1.79   | -3.79    | 0.22     |
| Creatinine-increase | Everolimus                  | yes vs no (ref)     | 19.59 | 2.98   | -0.45    | 6.40     |
|                 | Age                         | (continuous)        | 1.08 | 0.08   | 0.02     | 0.15     |
|                 | Gender                      | female vs male (ref)| 0.16 | 1.84   | -3.22    | -0.47    |
|                 | PRRT Line                   | > 2 vs 2 (ref)      | 0.12 | 2.15   | -5.38    | 1.07     |
| eGFR decrease   | Grading WHO2019             | G2 vs G1 (ref)      | 4.14 | 1.42   | -0.06    | 2.90     |
|                 | Age                         | continuous variable | 1.15 | 0.14   | 0.06     | 0.22     |
| Bilirubin-increase | MetNET                      | yes vs no (ref)     | 4.77 | 1.56   | -0.38    | 3.51     |
|                 | Age                         | (continuous)        | 1.05 | 0.05   | 0.01     | 0.11     |
|                 | Everolimus                  | yes vs no (ref)     | 0.21 | 1.54   | -3.53    | 0.45     |
| Albumine-increase | ECOG-PS                     | 1–2 vs 0 (ref)      | #    | 18.66  | 1.21     | 36.11    |
|                 | Everolimus                  | yes vs no (ref)     | #    | 16.64  | 0.41     | 32.87    |
|                 | Middgut-Foregut             | foregut vs middgut (ref) | 17.08 | 2.84   | -1.03    | 6.71     |
|                 | Age                         | (continuous)        | 0.55 | 0.61   | -1.18    | -0.03    |
|                 | N° of metastasis            | (continuous)        | 0.04 | 3.15   | -6.32    | 0.02     |
|                 | PRRT Line                   | > 2 vs 2 (ref)      | 0.00 | 14.19  | -28.33   | -0.04    |
Figure 1. Bootstrap results: frequency of inclusion of the covariates in the FLIC model, by outcome. Grading: WHO grading.
9. Strosberg, J. R.
7. Norlén, O.
8. Ahmed, A.
6. Lawrence, B.

16. Efficacy and safety of 177Lu-edotreotide PRRT in GEP-NET patients—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/
11. Yao, J. C.
12. Sahu, A.
13. De Mestier, L.

1. Dasari, A. et al. Trends in the incidence, prevalence and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335–1342 (2017).
2. Fraenkel, M. et al. Incidence of gastro-enteropancreatic neuroendocrine tumours: A systematic review of the literature. Endocr. Relat. Cancer. 21, R153–R163 (2014).
3. Leoncini, E. et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 58, 368–379 (2017).
4. Huguet, I. et al. Changes in the epidemiology of neuroendocrine tumours. Neuroendocrinology 104, 105–111 (2017).
5. WHO Classification of Tumours Editorial Board; Digestive System Tumours, WHO Classification of Tumours. 5th ed. LARC Press. 2019.
6. Lawrence, B. et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. EndocrinoU. Metab. Clin. N. Am. 40(1), 1–18. https://doi.org/10.1016/j.ecl.2019.12.005 (2011).
7. Norlén, O. et al. Long-term results of surgery for small intestinal neuroendocrine tumours at a tertiary referral center. World J. Surg. 36(6), 1419–1431. https://doi.org/10.1007/s00268-011-1296-z (2012).
8. Ahmed, A. et al. Midgut neuroendocrine tumours with liver metastasis: Results of the UKINETS study. Endocr. Relat. Cancer 16, 885–894 (2009).
9. Strosberg, J. R. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumours. N. Engl. J. Med. 376(2), 125–135. https://doi.org/10.1056/NEJMoai1607427 (2017).
10. Fazio, N. et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumours: RADIANT-4 lung subgroup analysis. Cancer Sci. 109(1), 174–181. https://doi.org/10.1111/cas.13427 (2018).
11. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumours. N. Engl. J. Med. 364, 514–523. https://doi.org/10.1056/NEJMa1098290 (2011).
12. Sahu, A. et al. CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumours: A single centre experience. J. Oncol. 2019, 9032753. https://doi.org/10.1155/2019/9032753 (2019).
13. De Mestier, L. et al. Comparison of temozolomide-capcitabine to 5-fluorouracil-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses. Neuroendocrinology 108(4), 343–353. https://doi.org/10.1159/000488877 (2019).
14. Nicolini, S. et al. Combined use of 177Lu-DOTATATE and metronomic capcitabine (Lu-X) in FDG-positive gastro-enteropancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging. https://doi.org/10.1007/s00259-021-05236-z (2021).
15. Brabander, T. et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumours. Clin. Cancer Res. 23(16), 4617–4624. https://doi.org/10.1158/1078-0432 (2017).
16. Efficacy and safety of 177Lu-edotreotide PRRT in GEP-NET patients—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03049189.
17. Study to evaluate the efficacy and safety of Lutathera in patients with grade 2 and grade 3 advanced GEP-NET—Full text view—ClinicalTrials.gov.gov; https://clinicaltrials.gov/ct2/show/NCT03972488.
18. Antitumor efficacy of peptide receptor radionuclide therapy with 177lutetium-octreotate randomized vs sunitinib in unresectable progressive well-differentiated neuroendocrine pancreatic cancer: First randomized phase II—Full text view—ClinicalTrials.gov.gov; https://clinicaltrials.gov/ct2/show/NCT0230176.
19. Pavel, M. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31(7), 844–860. https://doi.org/10.1016/j.annonc.2020.03.304 (2020).
20. Lutathera | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera.
21. AGENZIA ITALIANA DEL FARMACO | DETERMINA 11 marzo 2019. https://www.aifa.gov.it/documents/20142/847766/Deter-mina_501-2019_Lutathera.pdf.
22. Rudisile, S. et al. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pre-treated patients with metastatic neuroendocrine tumour (NET): Dosimetry, toxicity, efficacy, and survival. BMC Cancer 19, 788. https://doi.org/10.1186/s12885-019-6000-y (2019).
23. Panzuto, F. et al. Real-world study of everolimus in advanced progressive neuroendocrine tumours. Oncologist 19, 966–974 (2014).

Table 5. Average AUC obtained from subsampling, by outcome. The outcomes that have a predictive performance above 65% are highlighted in bold.

| Outcomes     | Mean AUC |
|--------------|----------|
| Leukopaenia  | 0.5574   |
| Neutropenia  | 0.4709   |
| Anaemia      | 0.6739   |
| Thrombocytopenia | 0.6199 |
| INR_increases| 0.4286   |
| AST_increases| 0.4652   |
| ALP_increases| 0.5941   |
| GGT_increases| 0.5485   |
| Bil_increases| 0.4876   |
| Creatinine_increases| 0.6503 |
| eGFR_decrease| 0.7282   |
| Albumine_decrease| 0.5331 |

Data availability
The data that support the findings of this study are available from the corresponding author (FS), upon reasonable request.

Received: 5 July 2021; Accepted: 16 September 2021
Published online: 30 September 2021

References
Acknowledgements

We would like to thank Dr S Massironi and Dr I Dellavedova for helping us to complete the database. We also thank the Associazione Italiana per la Ricerca sul Cancro (AIRC) for supporting our research.

Author contributions

Conception or design of the work: Marco Maccario, E.S., E.S., S.P., M.B., A.G. Data collection: F.S., A.G., N.P., G.C., M.K., V.F. Data analysis and interpretation: F.S., M.B., L.G., A.G., M.K. Drafting the article F.S., M.B., Marco Maccario, E.G. Critical revision of the article: Marco Maccario, E.S., S.P., M.B. Final approval of the version to be published: Marco Maccario, M.B., E.S., Massimo Milione.

Funding

The authors received financial support from the Associazione Italiana per la Ricerca sul Cancro (AIRC) to cover the Article Processing Charges (APC). The funders had no role in study design, data collection, analysis and decision to publish.

Competing interests

FS, Marco Maccario, Massimo Milione, ES, SP received honoraria as consultants and speakers from AAA, outside the submitted work. The remaining authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-99048-8.

Correspondence and requests for materials should be addressed to F.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.